Preclinical review of cerivastatin sodium—a step forward in HMG-CoA reductase inhibition
- 1 September 1998
- journal article
- review article
- Published by Elsevier in Atherosclerosis
- Vol. 139, 7-13
- https://doi.org/10.1016/s0021-9150(98)00188-9
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible MechanismsNew England Journal of Medicine, 1995
- Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS)Annals of Internal Medicine, 1993
- The discovery and development of HMG-CoA reductase inhibitors.Journal of Lipid Research, 1992
- Lowering of plasma cholesterol levels in animals by lovastatin and simvastatinEuropean Journal of Clinical Pharmacology, 1991
- CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal speciesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
- A Receptor-Mediated Pathway for Cholesterol HomeostasisScience, 1986
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog.Proceedings of the National Academy of Sciences, 1981
- Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.Proceedings of the National Academy of Sciences, 1980